OTC Artificial Tears Market Report by Product Types (Solution, Ointment, Emulsion, Gel, Spray Solution, and Suspensions), Application (Dry Eye Syndrome, Allergies, Infections, UV and Blue Light Protection, Contact Lens Moisture Retention, and Others), Distribution Channel (Drugstores & Supermarkets, Online Pharmacies, Retail Pharmacies, and Others), Regions and Company Analysis 2024-2030
Buy NowOTC Artificial Tears Market Analysis
Global OTC Artificial Tears Market is predicted to be valued at around US$ 6.25 Billion by 2030, according to Renub Research. The recognition and usage of over-the-counter (OTC) artificial tears have surged due to heightened recognition of eye fitness and the superiority of situations like dry eye syndrome. Consumers are increasingly turning to OTC artificial tears for convenient and instant relief from soreness, inflammation, and dryness. The accessibility of those products without a prescription and diverse formulations catering to unique needs has contributed to their considerable adoption. The developing trend displays a shift toward proactive eye care as people seek effective, on-the-go solutions for maintaining ocular well-being in their daily lives.
Global OTC Artificial Tears Market is envisioned to expand at a CAGR of 4.87% between 2024 and 2030
The growing prevalence of dry eye syndrome is a considerable driving force of the global OTC artificial tears market and increasing demand. Prevalence estimates vary globally, ranging from 9.5% to 90%, as per a BMC Ophthalmology report. This cognizance activates a growing range of modern and potential patients. Despite its non-vision-threatening nature, dry eye syndrome markedly reduces the quality of life, boosting market growth throughout the projection span.
Furthermore, the global over-the-counter (OTC) artificial tears market is propelled by the developing geriatric demographic and an uptick in eye surgical procedures. Besides, shifts in behaviors, consisting of prolonged exposure to digital screens and an upward thrust in smartphone dependency, contribute to dry eye syndrome, escalating demand for artificial tears, and fueling market enlargement. The current Center for Disease Control and Prevention (CDC) data reveals that children aged 8-18 spend 7.5 daily hours on screens, with 4.5 specifically on TV, amounting to 114 days yearly for screen entertainment. Moreover, the demand for artificial tear drops for post-operative management also rises with the growing quantity of eye surgical procedures. Hence, the Global OTC Artificial Tears Market was worth US$ 4.48 Billion in 2023.
Also, Europe is poised to become the region's significant over-the-counter (OTC) artificial tears market. Increasing times of age-associated ophthalmic problems and dry eye sicknesses propel this growth. According to the European Society of Retina Specialists (EURETINA), age-related macular degeneration (AMD) affects nearly 34 million people yearly in the European Union, with projections indicating a 25% upward thrust by 2050. Similarly, diabetic eye sicknesses are prevalent, with approximately four million Europeans affected, necessitating surgical intervention in 25% of instances and sooner or later boosting demand for artificial tears in post-operative care.
Consistent releases of present-day and ground-breaking products from prime companies further power the worldwide market during the forecast period. Such expected releases of modern products have continually raised patient population consciousness. Cutting-edge therapies and products may boost the market's ability to treat ocular conditions like dry eye syndrome and conjunctivitis. Recent launches from the SYSTANE family, like SYSTANE HYDRATION PF, and the Refresh family of artificial tears, like REFRESH RELIEVA, are predicted to spur over-the-counter (OTC) artificial tears market growth at some point in the projection period.
Solutions represent one of the prevalent product categories in the global OTC artificial tears market
The global OTC artificial tears market is fragmented into Solution, Ointment, Emulsion, Gel, Spray Solution, and Suspensions by product type. Solutions are among the dominant product types in the global over-the-counter (OTC) artificial tears market. This is because of their versatility and simplicity of use. These solutions quickly relieve numerous eye discomforts, including dryness and irritation, making them famous among customers searching for immediate comfort. Further, their liquid form allows for easy utility, catering to many users, such as those with sensitive eyes or contact lens wearers. As a result, solutions maintain an outstanding position in the OTC artificial tears market.
Dry eye syndrome is positioned for notable expansion within the over-the-counter (OTC) artificial tears market
By application, the global OTC artificial tears market is categorized into parts, including Allergies, Contact Lens Moisture Retention, Infections, UV and Blue Light Protection, Dry Eye Syndrome, and Other categories. Dry eye syndrome is poised for significant growth in the over-the-counter (OTC) artificial tears market. This surge is attributed to growing awareness and diagnosis of the situation, fueled by elements like growing elderly populations, increased display screen time, and environmental factors. As dry eye syndrome becomes more prevalent globally, the demand for OTC artificial tears, presenting convenient relief from symptoms like irritation and pain, is predicted to bounce. Thus, dry eye syndrome is expected to guide market growth as consumers seek accessible solutions for coping with this common ocular circumstance.
Drugstores and supermarkets may emerge as the primary distribution channels in the global OTC artificial tears market
By distribution channel, the global OTC artificial tears market is categorized into Drugstores & Supermarkets, Online Pharmacies, Retail Pharmacies, and Other segments. Drugstores and Supermarkets could become the leading segments in the global over-the-counter (OTC) artificial tears market. This is due to their extensive accessibility and comfort. These shops offer various artificial tear products, catering to a large client base seeking immediate relief for ocular soreness. Further, the familiarity and agreement with drugstores and supermarkets make them preferred destinations for getting healthcare products like artificial tears. Thus, their prominence in distribution channels solidifies their leading role in the market.
OTC artificial tears market in the United States is thriving
By country, the global OTC artificial tears market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, the Netherlands, and Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and New Zealand), Latin America (Brazil, Mexico, and Argentina), Middle East & Africa (South Africa, Saudi Arabia, and the UAE). The United States market for artificial tears is flourishing. This is propelled through widespread factors, including the growing prevalence of dry eye disease and eye infections. Recent records suggest a giant burden of dry eye sickness in the United States, affecting between sixteen million and forty-nine million Americans, representing 5-15% of the total population, with a higher occurrence among women. The growing demand for artificial tears, providing comfort from dry eyes, is anticipated due to this burden. Various factors expand demand, including exposure to blue light, mobile phone utilization, pollution, and dry climate conditions. Moreover, the market benefits from excessive disposable earnings, advanced healthcare facilities, and regulatory clearances, all contributing to its expansion.
Key Players
AbbVie Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Johnson & Johnson, Nicox S.A., Novartis AG, Santen Pharmaceutical Co. Ltd., and Sun Pharmaceutical Industries Ltd. are leading businesses in the global OTC artificial tears market.
- In December 2023 - Johnson & Johnson Vision Care initiated a phase II clinical trial to assess multi-dose preservative-free lubricating eye drops packaged in Novelia® Eye Dropper for non-contact lens users.
Product Types – Global OTC Artificial Tears Market breakup in 6 viewpoints:
1. Solution
2. Ointment
3. Emulsion
4. Gel
5. Spray Solution
6. Suspensions
Application – Global OTC Artificial Tears Market breakup in 6 viewpoints:
1. Dry Eye Syndrome
2. Allergies
3. Infections
4. UV and Blue Light Protection
5. Contact Lens Moisture Retention
6. Others
Distribution Channel – Global OTC Artificial Tears Market breakup in 4 viewpoints:
1. Drugstores & Supermarkets
2. Online Pharmacies
3. Retail Pharmacies
4. Others
Country – Global OTC Artificial Tears Market of 25 Countries:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis
Company Analysis:
1. AbbVie Inc.
2. Akorn Inc.
3. Alcon
4. Bausch Health Companies Inc.
5. Johnson & Johnson
6. Nicox S.A.
7. Novartis AG
8. Santen Pharmaceutical Co. Ltd.
9. Sun Pharmaceutical Industries Ltd.
Report Details:
| Report Features | Details |
| Base Year | 2023 |
| Historical Period | 2018 - 2023 |
| Forecast Period | 2024 - 2030 |
| Market | US$ Billion |
| Segment Covered | Product Type, Application, Distribution Channel, and Countries |
| Countries Covered | United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, and Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, and New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, and South Africa |
| Companies Covered | AbbVie Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Johnson & Johnson, Nicox S.A., Novartis AG, Santen Pharmaceutical Co. Ltd., and Sun Pharmaceutical Industries Ltd. |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |